论文部分内容阅读
高亲和性多聚体(Avimers)是新发展的一种由多个亲和单体聚集在一起的治疗性蛋白质,它包含了多个对靶分子的亲和结构域,每个结构域都具有结合某种靶点的能力,Avimers也可以同时对一个或多个靶点进行结合。在结构上,Avimers跟抗体是没有关联的,但它将同样具有与抗体相似的生物活性作用,因而在某种程度上可以作为抗体的替代物。由于Avimers对目标物具有高亲合性、高专一性,且低分子质量和低免疫原性,在一定程度上可以弥补传统抗体治疗所带来的局限性,因而非常有希望出现于临床应用中。文章试从Avimers的结构特征、功能特性、设计方法和作用机理等方面阐述其目前的研究现状,同时展望了它的应用的前景。
Avimers, a newly developed therapeutic protein assembled together by multiple affinity monomers, contain multiple affinity domains for a target molecule, each of which With the ability to bind to a target, Avimers can also bind one or more targets simultaneously. Structurally, Avimers are not associated with antibodies, but they will also have similar biological activity to antibodies and thus may serve as a substitute for antibodies to some extent. Due to the high affinity, high specificity, low molecular weight and low immunogenicity of the target, Avimers can somewhat compensate for the limitations of conventional antibody therapy and thus are very promising for clinical application in. The article tries to explain the current research status of Avimers from the aspects of its structure, function, design method and mechanism of action. At the same time, the prospect of its application is forecasted.